

AMENDMENTS TO THE CLAIMS

The following listing of the claims replaces all prior versions of the claims presented in the application.

1-13. (Cancelled).

14. (Currently amended) A humanized, monoclonal free-end specific antibody that binds specifically to a free N-terminus of an amyloid β -peptide that is soluble in cerebrospinal fluid (CSF) or to a free C-terminus of amyloid β peptide A β 1-40 that is soluble in CSF and does not bind to the amyloid β -precursor protein from which said amyloid β -peptide may be proteolytically derived.

15-22. (Cancelled)

23. (Currently amended) A humanized, single chain antibody that binds specifically to a free N-terminus of an amyloid β -peptide that is soluble in cerebrospinal fluid (CSF) or to a free C-terminus of amyloid β peptide A β 1-40 that is soluble in CSF and does not bind to the amyloid β -precursor protein from which said amyloid β -peptide may be proteolytically derived.

24. (Currently amended) The humanized, monoclonal antibody of claim 14 wherein said antibody is free-end specific for the free N-terminus of an amyloid β -peptide.

25-32. (Cancelled)

33. (Currently amended) The humanized, monoclonal antibody of claim 14 wherein said antibody is free-end specific for the free C-terminus of the amyloid β -peptide A β 1-40.

34. (Cancelled)

35. (Currently amended) [[A] The humanized, single chain antibody in accordance with claim 23, which is free-end specific for the free N-terminus of amyloid β -peptide.

36-37. (Cancelled)

38. (Currently amended) The humanized, single chain antibody of claim 23 wherein said antibody is free-end specific for the free C-terminus of the amyloid β -peptide A β 1-40.

39. (Currently amended) [[An]] A humanized, amyloid β -peptide neutralizing antibody that binds specifically to a free N-terminus of an amyloid β -peptide that is soluble in cerebrospinal fluid (CSF) or to a free C-terminus of amyloid β peptide A β 1-40 that is soluble in CSF and does not bind to the amyloid β -precursor protein from which said amyloid β -peptide may be proteolytically derived, and which inhibits neurotoxicity.

40. (Currently amended) [[An]] A humanized, amyloid β -peptide neutralizing single chain antibody that binds specifically to a free N-terminus of an amyloid β -peptide that is soluble in cerebrospinal fluid (CSF) or to a free C-terminus of amyloid β peptide A β 1-40 that is soluble in CSF and does not bind to the amyloid β -precursor protein from which said amyloid β -peptide may be proteolytically derived,

and which inhibits neurotoxicity.

41. (New) A composition comprising the humanized, monoclonal antibody of claim 14 and cerebrospinal fluid (CSF).

42. (New) The composition of claim 41 further comprising a complex of said humanized, monoclonal antibody and amyloid β -peptide.

43. (New) The composition of claim 42 wherein said amyloid β -peptide-antibody complex is a soluble complex.

44. (New) A composition comprising the humanized, single chain antibody of claim 23 and cerebrospinal fluid (CSF).

45. (New) The composition of claim 44 further comprising a complex of said humanized, single chain antibody and amyloid β -peptide.

46. (New) The composition of claim 45 wherein said amyloid β -peptide-antibody complex is a soluble complex.

47. (New) A composition comprising the humanized, amyloid β -peptide neutralizing single chain antibody of claim 40 and CSF.

48. (New) The composition of claim 47 further comprising a complex of said humanized, amyloid β -peptide neutralizing single chain antibody and amyloid β -peptide.

49. (New) The composition of claim 48 wherein said amyloid β -peptide-antibody complex is a soluble complex.

50. (New) A humanized, monoclonal antibody that specifically binds to an epitope within residues 1-5 of amyloid β -peptide and which binds soluble amyloid β -peptide but does not significantly bind amyloid precursor protein.

51. (New) A composition comprising the humanized, monoclonal antibody of claim 50 and cerebrospinal fluid (CSF).

52. (New) The composition of claim 51 further comprising a complex of said humanized, monoclonal antibody and said amyloid β -peptide.

53. (New) The composition of claim 52 wherein said amyloid β -peptide-antibody complex is a soluble complex.

54. (New) A humanized, monoclonal antibody that specifically binds to an epitope within residues 34-40 of said amyloid β -peptide and which binds soluble amyloid β -peptide but does not significantly bind amyloid precursor protein.

55. (New) A composition comprising the humanized, monoclonal antibody of claim 54 and cerebrospinal fluid (CSF).

56. (New) The composition of claim 55 further comprising a complex of said humanized, monoclonal antibody and said amyloid β -peptide.

57. (New) The composition of claim 56 wherein said amyloid β -peptide-antibody complex is a soluble complex.